FDA-cleared profile

EFAI NeuroSuite CT ICH Assessment System

Ever Fortune.AI Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone diagnostic or rule-out tool.

Clinical role
Passive case-level triage/notification and worklist prioritization with no image-region marking or direction of attention.
Images and patients
CT/CTA · Brain/head
Key limitation
Keep in mind: Not intended to address anomalies other than acute ICH, direct attention to image portions, provide stand-alone clinical decision-making, rule out hemorrhage, or preclude assessment of the CT study; full clinical review remains required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone diagnostic or rule-out tool.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head Input: DICOM-compliant adult non-contrast head CT studies with features suggestive of acute ICH.
  • Who uses it?Intended users: Radiologists and trained clinicians.
  • What does the software produce?Output: Binary case-level 'Suspected ICH: Yes or No' output to a PACS/workstation for worklist prioritization or triage; the device does not mark, highlight, or direct attention to a specific image location.
  • What is its most important limitation?Key limitation: Not intended to address anomalies other than acute ICH, direct attention to image portions, provide stand-alone clinical decision-making, rule out hemorrhage, or preclude assessment of the CT study; full clinical review remains required.

Clinical takeaway. Clinical role: Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone diagnostic or rule-out tool.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: retrospective, blinded, multisite validation of 288 CT studies (132 ICH positive, 156 negative) from 23 U.S. clinical sites, with three U.S. board-certified neuroradiologists and majority ground truth; the lower bounds of both 95% CIs were required to exceed 0.8. Standalone sensitivity was 0.947 (95% CI 0.895-0.974), specificity 0.949 (0.902-0.974), AUROC 0.983 (0.969-0.997), and mean processing time 34.96 seconds (33.89-36.03). Subgroup analyses covered demographic, manufacturer, slice-thickness, and ICH-type groups without replacing the overall endpoints.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone diagnostic or rule-out tool.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Passive case-level triage/notification and worklist prioritization with no image-region marking or direction of attention.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM-compliant adult non-contrast head CT studies with features suggestive of acute ICH.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Binary case-level 'Suspected ICH: Yes or No' output to a PACS/workstation for worklist prioritization or triage; the device does not mark, highlight, or direct attention to a specific image location.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Adult non-contrast head-CT triage workflow through a PACS/workstation; the FDA packet does not specify a narrower facility type.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists and trained clinicians.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Not intended to address anomalies other than acute ICH, direct attention to image portions, provide stand-alone clinical decision-making, rule out hemorrhage, or preclude assessment of the CT study; full clinical review remains required.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA packet: retrospective, blinded, multisite validation of 288 CT studies (132 ICH positive, 156 negative) from 23 U.S. clinical sites, with three U.S. board-certified neuroradiologists and majority ground truth; the lower bounds of both 95% CIs were required to exceed 0.8. Standalone sensitivity was 0.947 (95% CI 0.895-0.974), specificity 0.949 (0.902-0.974), AUROC 0.983 (0.969-0.997), and mean processing time 34.96 seconds (33.89-36.03). Subgroup analyses covered demographic, manufacturer, slice-thickness, and ICH-type groups without replacing the overall endpoints.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: retrospective, blinded, multisite validation of 288 CT studies (132 ICH positive, 156 negative) from 23 U.S. clinical sites, with three U.S. board-certified neuroradiologists and majority ground truth; the lower bounds of both 95% CIs were required to exceed 0.8. Standalone sensitivity was 0.947 (95% CI 0.895-0.974), specificity 0.949 (0.902-0.974), AUROC 0.983 (0.969-0.997), and mean processing time 34.96 seconds (33.89-36.03). Subgroup analyses covered demographic, manufacturer, slice-thickness, and ICH-type groups without replacing the overall endpoints.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Standalone adult non-contrast head-CT ICH endpoint: 0.947 (95% CI 0.895-0.974).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

This is the overall FDA validation sensitivity; the 0.8 value is the lower-bound acceptance goal, not sensitivity.

Reported specificity
Standalone adult non-contrast head-CT ICH endpoint: 0.949 (95% CI 0.902-0.974).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

This is the overall FDA validation specificity; AUROC and processing time are separate endpoints.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

EFAI NeuroSuite CT ICH Assessment System regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231025
  • Samplen=288
  • Sites23
  • IndependenceIndependence not established

K231025

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231025. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant adult non-contrast head CT studies with features suggestive of acute ICH.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K231025: EFAI NeuroSuite CT ICH Assessment System

  2. Routing

    Source context, not route validation: The FDA packet describes DICOM-compliant input and case-level output to a PACS/workstation; exact interface versions, routing behavior, and local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K231025: EFAI NeuroSuite CT ICH Assessment System

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-09 ·

  4. Returned objects

    Source context, not route validation: Binary case-level 'Suspected ICH: Yes or No' output to a PACS/workstation for worklist prioritization or triage; the device does not mark, highlight, or direct attention to a specific image location.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K231025: EFAI NeuroSuite CT ICH Assessment System

  5. Viewer/worklist/report

    Unresolved route: Binary case-level 'Suspected ICH: Yes or No' output to a PACS/workstation for worklist prioritization or triage; the device does not mark, highlight, or direct attention to a specific image location.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K231025: EFAI NeuroSuite CT ICH Assessment System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA packet describes DICOM-compliant input and case-level output to a PACS/workstation; exact interface versions, routing behavior, and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for EFAI NeuroSuite CT ICH Assessment System; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231025
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Brain/head
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-10-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K231025 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-09 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K231025: EFAI NeuroSuite CT ICH Assessment System

    U.S. Food and Drug Administration - Published 2023-10-04 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. EFAI NeuroSuite CT ICH Assessment System model card (K231025)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231025

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K231025 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K231384

Annalise Enterprise CTB Triage Trauma

Annalise-AI Pty Ltd.

Authorized purpose: Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out tool.

Modality
CT/CTA
Anatomy
Brain/head
Decision
2023-09-22
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24
FDA-cleared K251983

Brainomix 360 Triage Stroke

Brainomix Limited

Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.

Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Decision
2025-08-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history